Many PDG clients have found the 505(b)(2) NDA development pathway to be a more timely and cost-effective route to market. The 505(b)(2) pathway basically involves changing an already approved product to create a new drug with either a new indication, formulation, target population or other differences requiring. Call : 08133332950 Email : info@pharmdevgroup.com Visit : https://pharmdevgroup.com/505b2-ndas/